Skip to main content
. 2017 Oct;38(10):1876–1883. doi: 10.3174/ajnr.A5299

Table 2:

Measurements of absolute CBFmax and rCBFmax in each WHO grade with or without the exclusion of oligodendrogliomas and anaplastic oligodendrogliomas

Patients/Grades No. CBFmax (mL/100 g/min)
rCBFmax
Tumor Contralateral
All
    Grade II 13 85.8 ± 30.3 85.3 ± 16.4 1.03 ± 0.41
    Grade III 17 146.4 ± 84.0b 80.0 ± 16.1 1.81 ± 0.96c
    Grade IV 28 171.5 ± 58.7d 77.0 ± 10.9 2.25 ± 0.15d
Excludeda
    Grade II 9 75.1 ± 10.4 87.7 ± 18.6 0.88 ± 0.16
    Grade III 13 126.1 ± 74.7e 80.4 ± 16.6 1.52 ± 0.77b
    Grade IV 28 171.5 ± 58.7d,f 77.0 ± 10.9 2.25 ± 0.15d,g
a

With oligodendrogliomas and anaplastic oligodendrogliomas excluded. Note the following P values in each patient group:

b

P < .05, compared with grade II.

c

P < .01, compared with grade II.

d

P < .001, compared with grade II.

e

P = .05, compared with grade II.

f

P < .05, compared with grade III.

g

P < .01, compared with grade III.